548 related articles for article (PubMed ID: 26366475)
1. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.
Pitisuttithum P; Velicer C; Luxembourg A
Expert Rev Vaccines; 2015; 14(11):1405-19. PubMed ID: 26366475
[TBL] [Abstract][Full Text] [Related]
2. [The first vaccine against cancer: the human papillomavirus vaccine].
Bősze P
Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
[TBL] [Abstract][Full Text] [Related]
3. From the monovalent to the nine-valent HPV vaccine.
Pils S; Joura EA
Clin Microbiol Infect; 2015 Sep; 21(9):827-33. PubMed ID: 25980355
[TBL] [Abstract][Full Text] [Related]
4. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
Goldstone SE; Vuocolo S
Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023
[TBL] [Abstract][Full Text] [Related]
5. 9-Valent human papillomavirus vaccine: a review of the clinical development program.
Luxembourg A; Moeller E
Expert Rev Vaccines; 2017 Nov; 16(11):1119-1139. PubMed ID: 28956458
[TBL] [Abstract][Full Text] [Related]
6. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
McCormack PL; Joura EA
Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
[TBL] [Abstract][Full Text] [Related]
7. [Diseases caused by human papillomavirus -- the possibilities and the public health advantages of prevention].
Acs N; Bata Z; Danko D; Hernádi Z; Kálmán M; Kornya L; Kovács J; Mézáros G; Molnár MP; Mór Z; Novák Z; Sobel G; Szentirmay Z; Takács L; Tisza T
Orv Hetil; 2012 Dec; 153 Suppl():3-38. PubMed ID: 23687666
[No Abstract] [Full Text] [Related]
8. Human papillomavirus and genital cancer.
Rapose A
Indian J Dermatol Venereol Leprol; 2009; 75(3):236-43; quiz 243-4. PubMed ID: 19439875
[TBL] [Abstract][Full Text] [Related]
9. HPV vaccine update: new indications and controversies.
Mendoza N; Hernandez PO; Tyring SK
Skin Therapy Lett; 2011 Sep; 16(8):1-3. PubMed ID: 22089414
[TBL] [Abstract][Full Text] [Related]
10. Could the human papillomavirus vaccine prevent recurrence of ano-genital warts?: a systematic review and meta-analysis.
Husein-ElAhmed H
Int J STD AIDS; 2020 Jun; 31(7):606-612. PubMed ID: 32438856
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
Broomall EM; Reynolds SM; Jacobson RM
Postgrad Med; 2010 Mar; 122(2):121-9. PubMed ID: 20203463
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic human papillomavirus vaccines: past, present and future.
Anderson LA
Pathology; 2012 Jan; 44(1):1-6. PubMed ID: 22157686
[TBL] [Abstract][Full Text] [Related]
14. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
Saraiya M; Unger ER; Thompson TD; Lynch CF; Hernandez BY; Lyu CW; Steinau M; Watson M; Wilkinson EJ; Hopenhayn C; Copeland G; Cozen W; Peters ES; Huang Y; Saber MS; Altekruse S; Goodman MT;
J Natl Cancer Inst; 2015 Jun; 107(6):djv086. PubMed ID: 25925419
[TBL] [Abstract][Full Text] [Related]
15. Adolescent sexual activity and cancer risk: physicians' duty to inform?
Quinn GP; Vadaparampil ST; Johns T; Alexander KA; Giuliano AR
Curr Med Res Opin; 2014 Sep; 30(9):1827-31. PubMed ID: 24834953
[TBL] [Abstract][Full Text] [Related]
16. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
Riethmuller D; Jacquard AC; Lacau St Guily J; Aubin F; Carcopino X; Pradat P; Dahlab A; Prétet JL
BMC Public Health; 2015 May; 15():453. PubMed ID: 25934423
[TBL] [Abstract][Full Text] [Related]
17. A human papillomavirus vaccine.
Med Lett Drugs Ther; 2006 Aug 14-28; 48(1241-1242):65-6. PubMed ID: 16977280
[TBL] [Abstract][Full Text] [Related]
18. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.
Marty R; Roze S; Bresse X; Largeron N; Smith-Palmer J
BMC Cancer; 2013 Jan; 13():10. PubMed ID: 23298365
[TBL] [Abstract][Full Text] [Related]
19. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
20. Vaccines against human papillomavirus infections: protection against cancer, genital warts or both?
Joura EA; Pils S
Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S125-S127. PubMed ID: 28034371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
